Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.71M | $10.7M | $8.09M | $76.4M | $1.10B | $1.62B | $86.2M | $74.2M | $68.6M |
| Revenue growth | — | 293.9% | -24.2% | 843.9% | 1334.4% | 47.5% | -94.7% | -13.9% | -7.6% |
| Operating income | -$81.5M | -$119M | -$178M | -$297M | $421M | $833M | -$684M | -$587M | -$479M |
| Operating margin | -3009.5% | -1112.6% | -2199.7% | -388.9% | 38.4% | 51.6% | -794.0% | -791.3% | -699.2% |
| Net income | -$69.9M | -$116M | -$175M | -$299M | $529M | $516M | -$615M | -$522M | -$438M |
| Net margin | -2579.5% | -1086.3% | -2159.0% | -391.1% | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (diluted) | -$32.45 | -$15.12 | -$5.76 | -$2.51 | $3.96 | $3.83 | -$4.59 | -$3.83 | -$3.16 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.4M | -$94.1M | -$130M | -$191M | -$47.6M | $1.66B | -$779M | -$446M | -$392M |
| Capital expenditures | $2.74M | $8.19M | $8.94M | $6.55M | $21.8M | $68.0M | $21.6M | $7.30M | $4.83M |
| Free cash flow | -$69.1M | -$102M | -$139M | -$197M | -$69.4M | $1.60B | -$800M | -$454M | -$397M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $188M | $47.6M | $109M | $437M | $348M | $849M | $242M | $223M | $232M |
| Total assets | — | $192M | $512M | $919M | $1.95B | $2.80B | $1.92B | $1.40B | $1.00B |
| Total liabilities | — | $61.6M | $88.1M | $202M | $522M | $724M | $329M | $248M | $238M |
| Shareholders' equity | -$68.9M | -$179M | $424M | $717M | $1.43B | $2.08B | $1.59B | $1.15B | $765M |
| Retained earnings | — | -$194M | -$369M | -$667M | -$139M | $377M | -$238M | -$760M | -$1.20B |
| Shares (wtd avg diluted) | — | 8.86M | 30.3M | 119M | 133M | 135M | 134M | 136M | 139M |
Every figure is extracted from Vir Biotechnology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.